You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 128 No. 9, September 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (2)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Surgical Oncology
 •Prognosis/ Outcomes
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

A Staging System for Congenital Cholesteatoma

William P. Potsic, MD, MMM; Daniel S. Samadi, MD; Roger R. Marsh, PhD; Ralph F. Wetmore, MD

Arch Otolaryngol Head Neck Surg. 2002;128:1009-1012.

Objective  To develop a staging system for congenital cholesteatoma in predicting the likelihood of residual disease.

Design  Retrospective analysis of data from a case series, to identify predictors of residual disease.

Setting  Tertiary care pediatric hospital.

Participants  Children undergoing surgical removal of congenital cholesteatoma. There were 156 patients, with 160 cholesteatomas; 4 children had bilateral disease.

Interventions  Each case was scored as to quadrants of the middle ear involved, ossicular involvement, and mastoid extension.

Main Outcome Measure  Surgically confirmed residual disease at any time after the initial procedure.

Results  Four stages were defined as follows: stage I, disease confined to a single quadrant; stage II, cholesteatoma in multiple quadrants, but without ossicular involvement or mastoid extension; stage III, ossicular involvement without mastoid extension; and stage IV, mastoid disease. There was a strong association between stage and residual disease, ranging from a 13% risk in stage I to 67% in stage IV.

Conclusions  This simple staging system may be particularly useful in standardizing the reporting of congenital cholesteatoma and in adjusting for severity in evaluating outcomes. It also provides information that is useful in counseling parents.


From the Division of Pediatric Otolaryngology, The Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Congenital Cholesteatoma Associated with Blue Eardrum
JANG et al.
In Vivo 2009;23:163-166.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.